Core Viewpoint - Haier Biomedical (688139.SH) reported its 2025 performance, showing a slight increase in revenue but a significant decline in net profit [1] Group 1: Financial Performance - The company achieved operating revenue of 2.33 billion yuan, representing a year-on-year growth of 2.0% [1] - The net profit attributable to shareholders was 250 million yuan, reflecting a year-on-year decrease of 31.6% [1] Group 2: Revenue Breakdown - Overseas revenue reached 840 million yuan, marking a year-on-year increase of 17.9%, accounting for a record high of 36% of total revenue, up 5 percentage points from 2024 [1] - Revenue from the European region grew by 16.0%, the Asia-Pacific region by 26.0%, the Americas by 12.2%, and Africa by 17.8% [1] - Domestic revenue was 1.47 billion yuan, showing a year-on-year decline of 5.5% [1] Group 3: Industry Segmentation - New industry revenue accounted for 48.5% of total revenue, with a year-on-year growth rate of 8.8% [1] - Low-temperature storage industry revenue made up 51.5% of total revenue, experiencing a year-on-year decline of 3.9% [1] - Following a positive growth in the third quarter, the fourth quarter showed accelerated growth, indicating a gradual recovery from the bottom [1]

证券代码：688139 证券简称：海尔生物 公告编号：2026-006 青岛海尔生物医疗股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以青岛海尔生物医疗股份有限公司（以下简称"公司"）2025年年 度报告中披露的数据为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 | 项目 | 本报告期末 | 本报告期初 | 增减变动幅度（％） | | --- | --- | --- | --- | | 总资产 | 579,151.49 | 578,746.88 | 0.07 | | 归属于母公司的所有者 | 437,569.71 | 437,155.05 | 0.09 | | 权益 | | | | | 股本 | 31,795.25 | 31,795.25 | - | | 归属于母公司所有者的 | 13.76 | 13.75 | 0.07 | | 每股净资产（元） | | | | 注：1.本报 ...

Group 1 - The company reported a revenue of 2.33 billion yuan for 2025, representing a year-on-year growth of 2.0%, continuing the acceleration from 2024 [1] - In Q4 2025, the revenue growth rate was 13.1%, indicating a sustained internal growth momentum [1] - The overseas revenue reached 840 million yuan, a year-on-year increase of 17.9%, accounting for 36% of the main revenue, up 5 percentage points from 2024 [1] Group 2 - Domestic revenue was 1.47 billion yuan, down 5.5% year-on-year, but showed a recovery trend with a 14.5% growth in Q4 [1] - The company is focusing on AI and automation technology, with AI-related revenue making up 15% of total revenue, an increase of 2.5 percentage points from 2024 [1] - The net profit attributable to the parent company was 250 million yuan, a decline of 31.6% year-on-year [1] Group 3 - The gross margin for the reporting period was 46.8%, affected by the ramp-up of new factory capacity, but improved by approximately 0.7 percentage points in Q4 [2] - The company is investing in long-term strategies to address external challenges, focusing on globalization and innovation [2] - New localized operational systems were established in six locations, including Japan and Brazil, to enhance market promotion in Asia-Pacific and Europe [2]

海尔生物发布业绩快报，2025年度公司实现营业总收入23.29亿元，同比增长1.96%；净利润2.51亿元， 同比下降31.61%。2025年公司实现归母净利润2.5亿元，同比下滑31.6%。受外部环境、新建产能爬坡和 公司主动对海外、研发的中长期战略投入影响。 ...

Core Insights - Haier Biomedical (688139.SH) reported a revenue of 2.33 billion yuan for 2025, marking a year-on-year growth of 2.0%, continuing the acceleration from 2024 [1] - The company achieved an overseas revenue of 840 million yuan, a year-on-year increase of 17.9%, which accounted for 36% of total revenue, up 5 percentage points from 2024 [1] - Domestic revenue reached 1.47 billion yuan, down 5.5% year-on-year, but showed a recovery trend with a 14.5% growth in the fourth quarter [1] Revenue Breakdown - Fourth quarter revenue growth was 13.1% year-on-year, indicating sustained internal growth momentum [1] - Revenue from Europe grew by 16.0%, Asia-Pacific by 26.0%, Americas by 12.2%, and Africa by 17.8% [1] - AI-related revenue constituted 15% of total revenue, an increase of 2.5 percentage points from 2024 [1] Profitability and Margins - The gross margin for the reporting period was 46.8%, affected by the ramp-up of new factory capacities [2] - The net profit attributable to shareholders was 250 million yuan, a decline of 31.6% year-on-year [1] - The gross margin improved by approximately 0.7 percentage points in the fourth quarter compared to the previous quarter [2] Strategic Focus - The company is focusing on globalization and innovation as part of its long-term strategy, with significant investments in overseas market development [2] - New localized operational systems were established in Japan, Brazil, and four other locations to enhance market penetration in Asia-Pacific and Europe [2] - The company increased its technological innovation efforts, launching 11 new products, including automated systems and robots, to build higher barriers for long-term development [2]

Core Insights - The Chinese quick-freezing machine industry is at a critical juncture of opportunities and challenges, characterized by strong demand growth and accelerated technological upgrades. The market size is projected to reach approximately 3.946 billion yuan in 2024, representing a year-on-year growth of 10.35% [1][8]. Industry Overview - Quick-freezing machines, also known as freezing equipment, are industrial refrigeration devices primarily used for rapid freezing of food products. They function by using refrigeration systems and air circulation to lower the center temperature of items to below -18°C within 30 minutes, minimizing nutrient loss [2][4]. - The industry includes various types of quick-freezing machines, such as tunnel freezers, spiral freezers, fluidized freezers, and liquid nitrogen freezers [3]. Market Size - The growth in the quick-freezing machine market is driven by multiple demand engines, including the explosive growth of the prepared food industry, which increases the demand for high-end equipment like liquid nitrogen and spiral freezers. Additionally, the biopharmaceutical sector's requirements for ultra-low temperature storage and frost-free technology, along with the expansion of cold chain logistics, are contributing to the demand [1][7][8]. Industry Chain - The upstream of the quick-freezing machine industry includes raw materials and components such as steel, stainless steel, compressors, evaporators, fans, sensors, control systems, and environmentally friendly refrigerants. The midstream involves the manufacturing of quick-freezing machines, while the downstream applications span food processing, biopharmaceuticals, chemicals, and electronics [4]. Key Companies - The competitive landscape of the quick-freezing machine industry is characterized by leading companies such as Ice Wheel Environment, which offers a full-service capability from core compressors to large-scale spiral and tunnel freezing production lines. Ice Mountain Cold is also a key player with advanced technology in industrial refrigeration and commercial cold chain sectors [8][9][11]. Industry Development Trends 1. **Technological Innovation**: The focus is shifting from merely preserving food to enhancing its quality through advanced freezing technologies, such as the "cloud freezing" technology that minimizes cell damage and juice loss [13]. 2. **Customized Solutions**: The rapid growth of the prepared food industry is driving the need for diverse and refined equipment solutions, requiring quick-freezing machines to adapt to various food types and freezing requirements [14]. 3. **Smart and Green Development**: The industry's future will revolve around smart technologies and sustainability, integrating IoT, AI, and energy-efficient practices to enhance operational efficiency and reduce environmental impact [15].

Core Findings - The research indicates a significant positive correlation between good ESG practices and corporate brand value, with the environmental (E) and governance (G) dimensions having a more pronounced positive impact [2][9] - Under the "dual carbon" goals, companies' green production and energy-saving performance are more likely to gain international recognition, while governance structure optimization enhances market trust [2][3] - The social (S) dimension's impact on brand value is relatively weaker due to differences in standards between China and the West [2][3] ESG Practices and Corporate Governance - Leading companies typically adopt an embedded governance model for ESG, integrating it into strategic planning, product innovation, and supply chain management [2][3] - Hikvision has established a dual-axis governance structure, Huabao New Energy has developed a green factory system, BYD links ESG performance to executive compensation, and Haier Biomedical achieves a blend of commercial and social value through technological innovation [2][3] - These companies reflect a shift from "compliance-oriented" to "value-driven" ESG practices, aligning with international technical standards while retaining local characteristics [2][3] Challenges and Recommendations - Current challenges include non-unified ESG information disclosure standards, insufficient transformation capabilities of small and medium-sized enterprises, and the need for improved international discourse adaptability [3] - Recommendations include embedding ESG deeply into governance structures, constructing localized narrative systems, and enhancing industry chain collaboration [3] - The government should improve a tiered and categorized ESG standard system and establish diverse incentive mechanisms and public service platforms [3] Importance of ESG in Global Competitiveness - ESG has become a core indicator of corporate international competitiveness amid the global sustainable development agenda [3] - Chinese international enterprises need to implement systematic ESG practices to balance international standards with local adaptation, using environmental innovation as a breakthrough point to enhance brand value and international influence [3]

证券日报网讯2月3日，海尔生物在互动平台回答投资者提问时表示，截至2026年1月31日，公司股东总 数为14209户。 ...

Group 1 - Haier Biomedical's stock dropped by 3.42% on February 2, with a trading volume of 113 million yuan. The financing buy amount was 17.21 million yuan, while the financing repayment was 23.61 million yuan, resulting in a net financing buy of -6.39 million yuan. The total financing and securities balance reached 247 million yuan [1] - The financing balance of Haier Biomedical on February 2 was 245 million yuan, accounting for 2.41% of the circulating market value, which is above the 50th percentile level over the past year, indicating a relatively high position [1] - On the same day, Haier Biomedical repaid 2,300 shares in securities lending and sold 48,700 shares, with a selling amount of 1.57 million yuan. The securities lending balance was 175.06 million yuan, exceeding the 90th percentile level over the past year, also indicating a high position [1] Group 2 - As of January 20, the number of shareholders of Haier Biomedical reached 14,000, an increase of 5.33%, while the average circulating shares per person decreased by 5.06% to 22,571 shares [2] - For the period from January to September 2025, Haier Biomedical reported an operating income of 1.76 billion yuan, a year-on-year decrease of 1.17%, and a net profit attributable to shareholders of 198 million yuan, down 35.83% year-on-year [2] - Since its A-share listing, Haier Biomedical has distributed a total of 788 million yuan in dividends, with 452 million yuan distributed in the last three years [3]

Core Viewpoint - Haier Biomedical (688139.SH) announced a share reduction plan by its shareholder, Qingdao Haichuangrui Equity Investment Fund Center, due to funding needs, intending to reduce up to 0.85% of its total shares, equating to a maximum of 2,690,189 shares [1] Group 1 - Haichuangrui plans to reduce its holdings in Haier Biomedical through centralized bidding, with a reduction period starting 15 trading days after the announcement and lasting for three months [1] - As of the last trading day before the announcement, Haier Biomedical's share price was 33.34 yuan per share, estimating the reduction amount to be approximately 89.69 million yuan [1] - Haichuangrui currently holds 32,103,659 shares of Haier Biomedical, representing 10.14% of the total share capital [1] Group 2 - Haichuangrui has signed a voting rights entrustment agreement with Haier Group, establishing a concerted action relationship [2] - Haier Group, through its controlled entity, Qingdao Haier Biomedical Medical Holdings, holds 100,591,463 shares, accounting for 31.78% of Haier Biomedical's total shares [2] - Another concerted action partner, Qingdao Haichuangzhi Management Consulting Enterprise, holds 8,675,900 shares, representing 2.74% of the total shares [2] Group 3 - Haier Biomedical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 25, 2019, after receiving approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [3] - The company issued a total of 79,267,940 shares at a price of 15.53 yuan per share, raising approximately 1.23 billion yuan, with actual funds received amounting to about 1.16 billion yuan [3] - The funds were verified by Ernst & Young Hua Ming and were received on October 22, 2019, with Guotai Junan Securities serving as the lead underwriter [3]